Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:34:35 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CPIX - CUMBERLAND PHARMACEUTICALS INC - https://www.cumberlandpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CPIX - Q0.13.37·5.640.13.91+0.328.9102.83678583.54  3.98  3.547.25  1.8517:52:35Feb 0415 min RT 2¢

Recent Trades - Last 10 of 858
Time ETExPriceChangeVolume
17:52:35Q3.900.3120
17:11:43Q3.900.31100
17:07:24Q3.900.311
17:00:52Q3.900.31830
16:45:50Q3.900.311
16:19:52Q3.980.392
16:16:03Q4.000.411
16:11:15Q3.990.409
16:11:15Q3.990.4016
16:10:04Q3.910.321

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 09:05U:CPIXNews ReleaseCumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
2025-12-08 09:05U:CPIXNews ReleaseCALDOLOR(TM) (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
2025-11-04 17:00U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
2025-10-28 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
2025-10-20 09:05U:CPIXNews ReleaseCUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
2025-10-13 09:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS' VIBATIV(TM) ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
2025-10-01 09:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
2025-09-29 09:05U:CPIXNews ReleaseTABUK LAUNCHES VIBATIV(TM) FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
2025-08-05 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
2025-08-04 09:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV(TM) 4-VIAL STARTER PAK
2025-07-29 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
2025-06-23 09:05U:CPIXNews ReleaseCumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
2025-05-27 16:05U:CPIXNews ReleaseNEW STUDY FINDS CALDOLOR(TM) SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
2025-05-13 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
2025-05-06 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
2025-04-29 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
2025-03-19 16:05U:CPIXNews ReleaseFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
2025-03-04 16:05U:CPIXNews ReleaseCumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
2025-02-25 16:05U:CPIXNews ReleaseCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
2025-02-18 07:30U:CPIXNews ReleaseVIBATIV(TM) RECEIVES MARKETING APPROVAL IN CHINA